Dallas, TX -- (SBWIRE) -- 10/29/2014 -- “This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects.

Multiple sclerosis (MS), also known as disseminated sclerosis or encephalomyelitis disseminata, is an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a wide range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may disappear completely; however, permanent neurological problems often occur, especially as the disease advances.

Complete Report Available
http://www.rnrmarketresearch.com/multiple-sclerosis-pipeline-review-h2-2014-market-report.html .

Multiple Sclerosis - Companies Involved in Therapeutics Development:

Genzyme Corporation; Biogen Idec Inc.; Advanced Cell Technology, Inc.; Athersys, Inc.; GlaxoSmithKline plc; Inovio Pharmaceuticals, Inc. ; MedImmune, LLC; Biotest AG; Alkermes Plc; Plexxikon Inc.; Apitope International NV; Hanwha Chemical Co., Ltd.; Aphios Corporation; Acorda Therapeutics, Inc.; Biocon Limited; Eisai Co., Ltd.; Mitsubishi Tanabe Pharma Corporation; Ono Pharmaceutical Co., Ltd.; Pfizer Inc.; Rigel Pharmaceuticals, Inc.; Vertex Pharmaceuticals Incorporated; Zydus Cadila Healthcare Limited; Paratek Pharmaceuticals, Inc.; OPKO Health, Inc.; BrainStorm Cell Therapeutics Inc.; Merck KGaA

4SC AG; Addex Therapeutics Ltd; Evotec AG; Harbor Therapeutics, Inc.; Neuralstem, Inc.; Idera Pharmaceuticals, Inc.; Karo Bio AB; Almirall, S.A.; Lpath, Inc.; Bionomics Limited; MultiCell Technologies, Inc.; Neuren Pharmaceuticals Limited; Catalyst Pharmaceutical Partners, Inc.; Compugen Ltd.; Critical Outcome Technologies Inc.; Acadia Pharmaceuticals Inc. ;RegeneRx Biopharmaceuticals, Inc.; NeoStem, Inc.; Array BioPharma Inc. ; Xenetic Biosciences plc; HanAll Biopharma Co., Ltd; LG Life Sciences, Ltd.; Pluristem Therapeutics Inc.; Resverlogix Corp. ; Sareum Holdings plc; InDex Pharmaceuticals AB; Morphotek, Inc.; Digna Biotech, S.L.; Antipodean Pharmaceuticals, Inc.; Antitope Ltd.; Axxam SpA

Pieris AG; Hutchison MediPharma Limited; Argos Therapeutics, Inc.; Affectis Pharmaceuticals AG; Coronado Biosciences, Inc.; MacroGenics, Inc.; Q Therapeutics, Inc.; Catabasis Pharmaceuticals, Inc.; Vaccinex, Inc.; Kineta, Inc.; MSM Protein Technologies, Inc.; Vascular Biogenics Ltd.; Endocyte, Inc.; Theraclone Sciences, Inc.; Effimune SAS; InteKrin Therapeutics, Inc.; Siena Biotech S.p.A.; Virogenomics, Inc.; Omeros Corporation; Bolder Biotechnology, Inc.; Aegis Therapeutics, LLC; Dimerix Bioscience Pty Ltd; Cellceutix Corporation; Biovista Inc.; Invion Limited; SanBio, Inc.; KaloBios Pharmaceuticals, Inc.; Provid Pharmaceuticals, Inc.; Vitae Pharmaceuticals, Inc.; Biokine Therapeutics Ltd.; OncoImmune, Inc.

to-BBB technologies BV; KAHR medical Ltd.; Lycera Corp.; MAKScientific, LLC; RhinoCyte, Inc.; Vakzine Projekt Management GmbH; KAEL-GemVax Co., Ltd.; Pfenex Inc.; Vicore Pharma AB; Cellmid Limited; Synthon BV; Varinel, Inc.; Cognosci, Inc.; Immune Technologies and Medicine; Targazyme, Inc.; ProNoxis AB; Cell Cure Neurosciences, Ltd.; GeNeuro SA; VivaCell Biotechnology Espana S.L; Forward Pharma A/S; Genervon Biopharmaceuticals, LLC; Regenesance BV; Inbiopro Solutions Pvt. Ltd.; Kareus Therapeutics, SA; Lead Discovery Center GmbH; BRAINco Biopharma, S.L; Immunaffect B.V.; SOM Biotech SL; Immune Response BioPharma, Inc.; Bionure Farma, S.L.; IntelliCell BioSciences Inc.; The International Biotechnology Center (IBC) “Generium”; Arrien Pharmaceuticals, LLC; Creabilis SA; CalAsia

Pharmaceuticals, Inc.; Evgen Limited; SK Biopharmaceuticals Co., Ltd.; Io Therapeutics, Inc.; Lanthio; harma B.V.; ReveraGen BioPharma, Inc.; Ossianix, Inc.; Endece, LLC; Biomar Microbial Technologies

GliaCure Inc. ; ImmuNext, Inc.; Toleranzia AB; Mapi Pharma Ltd.; Regeneks; Glialogix, Inc.; Bionature E.A. Ltd.; Dong-A Socio Group.

Order a Purchase copy
http://www.rnrmarketresearch.com/contacts/purchase?rname=235011

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.

Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope:

-The report provides a snapshot of the global therapeutic landscape of Multiple Sclerosis

-The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in the therapeutics development for Multiple Sclerosis and enlists all their major and minor projects

-The report summarizes all the dormant and discontinued pipeline projects

-A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-A detailed assessment of monotherapy and combination therapy pipeline projects

-Coverage of the Multiple Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type

-Latest news and deals relating related to pipeline products

Reasons to buy:

-Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Develop strategic initiatives by understanding the focus areas of leading companies

-Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis

-Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

-Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

-Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse more reports on Multiple Sclerosis Drugs Market
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/multiple-sclerosis-drugs